Skip to main
ANAB

AnaptysBio (ANAB) Stock Forecast & Price Target

AnaptysBio (ANAB) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

AnaptysBio Inc has shown a positive financial outlook due to a beneficial settlement with GSK, resulting in an increase in royalty rates for Jemperli sales and a one-time cash infusion of $60 million. This settlement enhances confidence in AnaptysBio's business model, as it signals operational stability while maintaining adequate capital to support ongoing clinical-stage programs. Furthermore, the company's ongoing trials for immune cell modulating antibodies, including significant indications for autoimmune and inflammatory diseases, position AnaptysBio favorably for potential revenue growth and expanded partnership opportunities.

Bears say

AnaptysBio Inc faces significant risks that contribute to a negative outlook on its stock, primarily related to the safety and efficacy of its clinical programs, particularly for its lead candidates, rosnilimab and ANB032. The company is also vulnerable to greater-than-expected competition in the commercial landscape, which could undermine its market position and projected sales for its products, including Jemperli. Furthermore, unresolved legal issues and potential regulatory hurdles present additional uncertainties that could negatively impact investor confidence and the company’s financial performance.

AnaptysBio (ANAB) has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AnaptysBio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AnaptysBio (ANAB) Forecast

Analysts have given AnaptysBio (ANAB) a Buy based on their latest research and market trends.

According to 9 analysts, AnaptysBio (ANAB) has a Buy consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $64.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $64.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AnaptysBio (ANAB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.